Naltrexone ER/Bupropion ER: A Review in Obesity Management
Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave ® , Mysimba™) is available as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of ≥30 kg/m 2 (i.e. obese) or a BMI of ≥27 kg/m 2 (i.e....
Gespeichert in:
| Veröffentlicht in: | Drugs (New York, N.Y.) N.Y.), 2015-07, Vol.75 (11), p.1269-1280 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1280 |
|---|---|
| container_issue | 11 |
| container_start_page | 1269 |
| container_title | Drugs (New York, N.Y.) |
| container_volume | 75 |
| creator | Greig, Sarah L. Keating, Gillian M. |
| description | Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave
®
, Mysimba™) is available as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of ≥30 kg/m
2
(i.e. obese) or a BMI of ≥27 kg/m
2
(i.e. overweight) in the presence of at least one bodyweight-related comorbidity, such as type 2 diabetes mellitus, hypertension or dyslipidaemia. In 56-week phase III trials in these patient populations, oral naltrexone ER/bupropion ER 32/360 mg/day was significantly more effective than placebo with regard to percentage bodyweight reductions from baseline and the proportion of patients who achieved bodyweight reductions of ≥5 and ≥10 %. Significantly greater improvements in several cardiometabolic risk factors were also observed with naltrexone ER/bupropion ER versus placebo, as well as greater improvements in glycated haemoglobin levels in obese or overweight adults with type 2 diabetes. Naltrexone ER/bupropion ER was generally well tolerated in phase III trials, with nausea being the most common adverse event. Thus, naltrexone ER/bupropion ER 32/360 mg/day as an adjunct to a reduced-calorie diet and increased physical activity, is an effective and well tolerated option for chronic bodyweight management in obese adults or overweight adults with at least one bodyweight-related comorbidity. |
| doi_str_mv | 10.1007/s40265-015-0427-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1897377464</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1897377464</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-45de9e84c9d3847370de2bba560911990ac02d02d6205afb7132ca003a58dd283</originalsourceid><addsrcrecordid>eNqFkV1LwzAUhoMobn78AG-k4I03deekTdLsbopfoA5Er0Pano2Orp1N68e_N6NTRBAhIRzy5DlJXsaOEM4QQI1cDFyKENDPmKtQbLEhotIhagHbbAiAPJRSqgHbc26xLrXQu2zAJYJAlEM2frBl29B7XVFw-Tg671ZNvSrqyhfjYBI80mtBb0FRBdOUXNF-BPe2snNaUtUesJ2ZLR0dbtZ99nx1-XRxE95Nr28vJndhFivRhrHISVMSZzqPklhFCnLiaWqFBI2oNdgMeO6H5CDsLFUY8cwCRFYkec6TaJ-d9l5_tZeOXGuWhcuoLG1FdecMJtpbVSzj_1GpFcdEgvDoyS90UXdN5R9iUKHkGpVQnsKeyprauYZmZtUUS9t8GASzzsD0GRifgVlnYNbm4425S5eUf5_4-nQP8B5wfquaU_Oj9Z_WTxb5jYA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1716291757</pqid></control><display><type>article</type><title>Naltrexone ER/Bupropion ER: A Review in Obesity Management</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Greig, Sarah L. ; Keating, Gillian M.</creator><creatorcontrib>Greig, Sarah L. ; Keating, Gillian M.</creatorcontrib><description>Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave
®
, Mysimba™) is available as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of ≥30 kg/m
2
(i.e. obese) or a BMI of ≥27 kg/m
2
(i.e. overweight) in the presence of at least one bodyweight-related comorbidity, such as type 2 diabetes mellitus, hypertension or dyslipidaemia. In 56-week phase III trials in these patient populations, oral naltrexone ER/bupropion ER 32/360 mg/day was significantly more effective than placebo with regard to percentage bodyweight reductions from baseline and the proportion of patients who achieved bodyweight reductions of ≥5 and ≥10 %. Significantly greater improvements in several cardiometabolic risk factors were also observed with naltrexone ER/bupropion ER versus placebo, as well as greater improvements in glycated haemoglobin levels in obese or overweight adults with type 2 diabetes. Naltrexone ER/bupropion ER was generally well tolerated in phase III trials, with nausea being the most common adverse event. Thus, naltrexone ER/bupropion ER 32/360 mg/day as an adjunct to a reduced-calorie diet and increased physical activity, is an effective and well tolerated option for chronic bodyweight management in obese adults or overweight adults with at least one bodyweight-related comorbidity.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.1007/s40265-015-0427-5</identifier><identifier>PMID: 26105116</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adis Drug Evaluation ; Adult ; Animals ; Anti-Obesity Agents - administration & dosage ; Anti-Obesity Agents - adverse effects ; Anti-Obesity Agents - therapeutic use ; Appetite ; Body mass index ; Bupropion - administration & dosage ; Bupropion - adverse effects ; Bupropion - therapeutic use ; Calories ; Cardiovascular disease ; Comorbidity ; Delayed-Action Preparations ; Diabetes ; Dopamine ; Drug Combinations ; Drug therapy ; Endorphins ; Exercise ; Food ; Humans ; Hypertension ; Internal Medicine ; Medicine ; Medicine & Public Health ; Metabolic disorders ; Naltrexone - administration & dosage ; Naltrexone - adverse effects ; Naltrexone - therapeutic use ; Narcotics ; Obesity ; Obesity - drug therapy ; Overweight ; Overweight - drug therapy ; Pharmacology/Toxicology ; Pharmacotherapy ; Weight control</subject><ispartof>Drugs (New York, N.Y.), 2015-07, Vol.75 (11), p.1269-1280</ispartof><rights>Springer International Publishing Switzerland 2015</rights><rights>Copyright Springer Science & Business Media Jul 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-45de9e84c9d3847370de2bba560911990ac02d02d6205afb7132ca003a58dd283</citedby><cites>FETCH-LOGICAL-c475t-45de9e84c9d3847370de2bba560911990ac02d02d6205afb7132ca003a58dd283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40265-015-0427-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40265-015-0427-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,782,786,27931,27932,41495,42564,51326</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26105116$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Greig, Sarah L.</creatorcontrib><creatorcontrib>Keating, Gillian M.</creatorcontrib><title>Naltrexone ER/Bupropion ER: A Review in Obesity Management</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><addtitle>Drugs</addtitle><description>Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave
®
, Mysimba™) is available as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of ≥30 kg/m
2
(i.e. obese) or a BMI of ≥27 kg/m
2
(i.e. overweight) in the presence of at least one bodyweight-related comorbidity, such as type 2 diabetes mellitus, hypertension or dyslipidaemia. In 56-week phase III trials in these patient populations, oral naltrexone ER/bupropion ER 32/360 mg/day was significantly more effective than placebo with regard to percentage bodyweight reductions from baseline and the proportion of patients who achieved bodyweight reductions of ≥5 and ≥10 %. Significantly greater improvements in several cardiometabolic risk factors were also observed with naltrexone ER/bupropion ER versus placebo, as well as greater improvements in glycated haemoglobin levels in obese or overweight adults with type 2 diabetes. Naltrexone ER/bupropion ER was generally well tolerated in phase III trials, with nausea being the most common adverse event. Thus, naltrexone ER/bupropion ER 32/360 mg/day as an adjunct to a reduced-calorie diet and increased physical activity, is an effective and well tolerated option for chronic bodyweight management in obese adults or overweight adults with at least one bodyweight-related comorbidity.</description><subject>Adis Drug Evaluation</subject><subject>Adult</subject><subject>Animals</subject><subject>Anti-Obesity Agents - administration & dosage</subject><subject>Anti-Obesity Agents - adverse effects</subject><subject>Anti-Obesity Agents - therapeutic use</subject><subject>Appetite</subject><subject>Body mass index</subject><subject>Bupropion - administration & dosage</subject><subject>Bupropion - adverse effects</subject><subject>Bupropion - therapeutic use</subject><subject>Calories</subject><subject>Cardiovascular disease</subject><subject>Comorbidity</subject><subject>Delayed-Action Preparations</subject><subject>Diabetes</subject><subject>Dopamine</subject><subject>Drug Combinations</subject><subject>Drug therapy</subject><subject>Endorphins</subject><subject>Exercise</subject><subject>Food</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic disorders</subject><subject>Naltrexone - administration & dosage</subject><subject>Naltrexone - adverse effects</subject><subject>Naltrexone - therapeutic use</subject><subject>Narcotics</subject><subject>Obesity</subject><subject>Obesity - drug therapy</subject><subject>Overweight</subject><subject>Overweight - drug therapy</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Weight control</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkV1LwzAUhoMobn78AG-k4I03deekTdLsbopfoA5Er0Pano2Orp1N68e_N6NTRBAhIRzy5DlJXsaOEM4QQI1cDFyKENDPmKtQbLEhotIhagHbbAiAPJRSqgHbc26xLrXQu2zAJYJAlEM2frBl29B7XVFw-Tg671ZNvSrqyhfjYBI80mtBb0FRBdOUXNF-BPe2snNaUtUesJ2ZLR0dbtZ99nx1-XRxE95Nr28vJndhFivRhrHISVMSZzqPklhFCnLiaWqFBI2oNdgMeO6H5CDsLFUY8cwCRFYkec6TaJ-d9l5_tZeOXGuWhcuoLG1FdecMJtpbVSzj_1GpFcdEgvDoyS90UXdN5R9iUKHkGpVQnsKeyprauYZmZtUUS9t8GASzzsD0GRifgVlnYNbm4425S5eUf5_4-nQP8B5wfquaU_Oj9Z_WTxb5jYA</recordid><startdate>20150701</startdate><enddate>20150701</enddate><creator>Greig, Sarah L.</creator><creator>Keating, Gillian M.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7QO</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7TS</scope></search><sort><creationdate>20150701</creationdate><title>Naltrexone ER/Bupropion ER: A Review in Obesity Management</title><author>Greig, Sarah L. ; Keating, Gillian M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-45de9e84c9d3847370de2bba560911990ac02d02d6205afb7132ca003a58dd283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adis Drug Evaluation</topic><topic>Adult</topic><topic>Animals</topic><topic>Anti-Obesity Agents - administration & dosage</topic><topic>Anti-Obesity Agents - adverse effects</topic><topic>Anti-Obesity Agents - therapeutic use</topic><topic>Appetite</topic><topic>Body mass index</topic><topic>Bupropion - administration & dosage</topic><topic>Bupropion - adverse effects</topic><topic>Bupropion - therapeutic use</topic><topic>Calories</topic><topic>Cardiovascular disease</topic><topic>Comorbidity</topic><topic>Delayed-Action Preparations</topic><topic>Diabetes</topic><topic>Dopamine</topic><topic>Drug Combinations</topic><topic>Drug therapy</topic><topic>Endorphins</topic><topic>Exercise</topic><topic>Food</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic disorders</topic><topic>Naltrexone - administration & dosage</topic><topic>Naltrexone - adverse effects</topic><topic>Naltrexone - therapeutic use</topic><topic>Narcotics</topic><topic>Obesity</topic><topic>Obesity - drug therapy</topic><topic>Overweight</topic><topic>Overweight - drug therapy</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Weight control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Greig, Sarah L.</creatorcontrib><creatorcontrib>Keating, Gillian M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Physical Education Index</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Greig, Sarah L.</au><au>Keating, Gillian M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Naltrexone ER/Bupropion ER: A Review in Obesity Management</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><stitle>Drugs</stitle><addtitle>Drugs</addtitle><date>2015-07-01</date><risdate>2015</risdate><volume>75</volume><issue>11</issue><spage>1269</spage><epage>1280</epage><pages>1269-1280</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><abstract>Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave
®
, Mysimba™) is available as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of ≥30 kg/m
2
(i.e. obese) or a BMI of ≥27 kg/m
2
(i.e. overweight) in the presence of at least one bodyweight-related comorbidity, such as type 2 diabetes mellitus, hypertension or dyslipidaemia. In 56-week phase III trials in these patient populations, oral naltrexone ER/bupropion ER 32/360 mg/day was significantly more effective than placebo with regard to percentage bodyweight reductions from baseline and the proportion of patients who achieved bodyweight reductions of ≥5 and ≥10 %. Significantly greater improvements in several cardiometabolic risk factors were also observed with naltrexone ER/bupropion ER versus placebo, as well as greater improvements in glycated haemoglobin levels in obese or overweight adults with type 2 diabetes. Naltrexone ER/bupropion ER was generally well tolerated in phase III trials, with nausea being the most common adverse event. Thus, naltrexone ER/bupropion ER 32/360 mg/day as an adjunct to a reduced-calorie diet and increased physical activity, is an effective and well tolerated option for chronic bodyweight management in obese adults or overweight adults with at least one bodyweight-related comorbidity.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>26105116</pmid><doi>10.1007/s40265-015-0427-5</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-6667 |
| ispartof | Drugs (New York, N.Y.), 2015-07, Vol.75 (11), p.1269-1280 |
| issn | 0012-6667 1179-1950 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1897377464 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adis Drug Evaluation Adult Animals Anti-Obesity Agents - administration & dosage Anti-Obesity Agents - adverse effects Anti-Obesity Agents - therapeutic use Appetite Body mass index Bupropion - administration & dosage Bupropion - adverse effects Bupropion - therapeutic use Calories Cardiovascular disease Comorbidity Delayed-Action Preparations Diabetes Dopamine Drug Combinations Drug therapy Endorphins Exercise Food Humans Hypertension Internal Medicine Medicine Medicine & Public Health Metabolic disorders Naltrexone - administration & dosage Naltrexone - adverse effects Naltrexone - therapeutic use Narcotics Obesity Obesity - drug therapy Overweight Overweight - drug therapy Pharmacology/Toxicology Pharmacotherapy Weight control |
| title | Naltrexone ER/Bupropion ER: A Review in Obesity Management |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T01%3A31%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Naltrexone%20ER/Bupropion%20ER:%20A%20Review%20in%20Obesity%20Management&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=Greig,%20Sarah%20L.&rft.date=2015-07-01&rft.volume=75&rft.issue=11&rft.spage=1269&rft.epage=1280&rft.pages=1269-1280&rft.issn=0012-6667&rft.eissn=1179-1950&rft_id=info:doi/10.1007/s40265-015-0427-5&rft_dat=%3Cproquest_cross%3E1897377464%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1716291757&rft_id=info:pmid/26105116&rfr_iscdi=true |